NovoCure (NVCR) Convertible Debt (2023 - 2024)
NovoCure (NVCR) posted quarterly Convertible Debt of $556.5 million for Q2 2024, down 2.16% on a QoQ basis from $568.8 million in Q4 2023.
NovoCure (NVCR) Convertible Debt (2023 - 2024) Analysis & Trends
NovoCure (NVCR) has reported Convertible Debt for 2 consecutive years, with $556.5 million the latest figure, recorded in Q2 2024.
- Quarterly Convertible Debt changed N/A year-over-year to $556.5 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $556.5 million (changed N/A YoY) and the FY2023 annual result came in at $568.8 million, changed N/A from the prior year.
- Convertible Debt slipped to $556.5 million in Q2 2024 per NVCR's latest filing, from $568.8 million in the prior quarter.
- Over the last five years, Convertible Debt for NVCR reached as high as $568.8 million in Q4 2023 and fell as low as $556.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.13 Bn | 175.84 Bn | 6.27 Bn |
| 2 | Stryker | 128.86 Bn | 125.99 Bn | 3.81 Bn |
| 3 | Medtronic | 108.95 Bn | 99.73 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.42 Bn | 66.97 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.30 Bn | 44.63 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.33 Bn | 26.04 Bn | 1.98 Bn |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.30 Bn | 2.07 Bn |
| 10 | NovoCure | 2.01 Bn | 1.57 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 556.51 Mn |
| Dec 31, 2023 | 568.82 Mn |